Search results
Toddler's Snoring Turned Out to Be an Early Sign of Leukemia: 'We Were All Sobbing'
People via Yahoo News· 7 days agoAccording to the Daily Mail, her son, Mason, struggled to breathe at night and had a persistent high...
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at...
WKBN 27 Youngstown· 22 hours agoThis marked the first-in-human trial using CAR-NKT therapy for R/R mRCC, demonstrating a good safety profile and encouraging anti-tumor activity.
Study shows drug helps reprogram macrophage immune cells, suppress prostate and bladder tumor growth
Medical Xpress· 3 days agoImmunotherapies that help the immune system recognize and fight tumors have revolutionized care for...
MD Anderson Research Highlights: ASCO 2024 Special | Newswise
Newswise· 1 day agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 2 days agoFood and Drug Administration (FDA) has awarded Regenerative Medicine Advanced Therapy (RMAT)...
Researchers explore present and future treatment options for hepatocellular carcinoma using...
Medical Xpress· 2 days agoHepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms. The tumor microenvironment ...
Limula raises $6.8m to develop cell and gene therapy manufacturing platform
BioPharma-Reporter· 3 days agoThe company will use its new seed capital to ‘significantly advance’ its modular solution for...
AstraZeneca sets sights on $80B in revenue by 2030
BioPharma Dive via Yahoo Finance· 3 days agoFurther out, AstraZeneca is investing in new approaches to treat diseases, like CAR-T cell therapies for autoimmune disorders. “The breadth of our...
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Motley Fool via Yahoo Finance· 2 days agoAmtagvi is approved for advanced melanoma, the deadliest of skin cancers -- and this represents the...
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 16 hours agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...